


FIRST PLACE POSTER— Oncology, Basic Science

Songji Zhao, MD, PhD¹, Keiichiro Yoshinaga, MD, PhD², Komei Washino, VMD, PhD², Miho Aoki, Bpharm¹, Ken-ichi Nishijima, PhD¹, Saki Shimoyama, B.Agr¹, Naoyuki Ukon, PhD¹, Fengying Gao, PhD¹, Kohshin Washiyama, PhD¹, Natsue Ito, M.T², Naho Yoshioka, A.A², Naomi Tamura, PhD³, Kazuhiro Takahashi, PhD¹, Tatsuya Higashi, MD, PhD², Hiroshi Ito, MD, PhD⁴,
¹Advanced Clinical Research Center, Fukushima Global Medical Science Center, Fukushima Medical University, Fukushima, Japan,
²National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan,
³Research Center for Medical and Health Data Science, The Institute of Statistical Mathematics, Tachikawa, Japan, ⁴Department of Radiology and Nuclear Medicine, Fukushima Medical University, Fukushima, Japan

Poster #1316: Effects and safety of alpha-emitting meta-²¹¹At-astato-benzylguanidine (²¹¹At-MABG) compared with ¹³¹I-meta-iodobenzylguanidine (¹³¹I-MIBG) on tumor growth suppression in a pheochromocytoma mouse model

July 14, 2020

*67th Annual Meeting of the SNMMI
Advancing Molecular Imaging and Therapy
Virtual Edition*


Umar Mahmood, MD, PhD
Chair, Scientific Program Committee